GeneDx reported results from its SAVES-Kids health economics analysis of whole exome and whole genome sequencing in children with neurodevelopmental disorders, including epilepsy and developmental delay or intellectual disability. The findings were presented at the ACMG Annual Meeting in Baltimore. In children with epilepsy, average total healthcare costs decreased 61% from USD 130,048 per patient per year before testing to USD 50,798 in the 12 months after testing. Among Medicaid-covered children with epilepsy, total healthcare costs decreased 53% in the year after testing, alongside 80% fewer hospitalizations. In children with developmental delay or intellectual disability, total healthcare costs decreased 19% in the first year after testing, with 80% fewer hospitalizations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260311695167) on March 11, 2026, and is solely responsible for the information contained therein.
Comments